DZ2002

TargetMol
Product Code: TAR-T11134
Supplier: TargetMol
CodeSizePrice
TAR-T11134-1mg1mg£182.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-2mg2mg£230.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-5mg5mg£349.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-1mL1 mL * 10 mM (in DMSO)£377.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-10mg10mg£470.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-25mg25mg£707.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-50mg50mg£978.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-100mg100mg£1,291.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T11134-500mg500mg£2,456.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
DZ2002 is a potent and reversible S-Adenosyl-L-homocysteine Hydrolase(SAHH; AdoHcy Hydrolase) inhibitor with Ki of 17.9 nM. IC50 value: 17.9 nM(Ki).
CAS:
33231-14-0
Formula:
C10H13N5O3
Molecular Weight:
251.246
Purity:
0.98
SMILES:
COC(=O)C(O)CCn1cnc2c(N)ncnc12

References

1. Wu QL, et al. Inhibition of S-adenosyl-L-homocysteine hydrolase induces immunosuppression. J Pharmacol Exp Ther. 2005 May;313(2):705-11. 2. Fu YF, et al. S-adenosyl-L-homocysteine hydrolase inactivation curtails ovalbumin-induced immune responses. J Pharmacol Exp Ther. 2006 Mar;316(3):1229-37. 3. He SJ, et al. Therapeutic effects of DZ2002, a reversible SAHH inhibitor, on lupus-prone NZB?NZW F1 mice via interference with TLR-mediated APC response. Acta Pharmacol Sin. 2014 Feb;35(2):219-29.